Nonalcoholic steatohepatitis (NASH) is the advanced subtype of nonalcoholic fatty liver disease (NAFLD) and is becoming a severe global public health problem. PPAR¦Á/¦Ä are regarded as potential therapeutic targets for NASH. Herein, researchers report a series of novel triazolone derivatives as PPAR¦Á/¦Ä dual agonists.

The pharmacokinetic studies were conducted by Medicilon.

The hERG channel inhibition studies were conducted by Medicilon.

The Ames tests were conducted by Medicilon.

Reference:

Zhiqi Feng, et al. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR¦Á/¦Ä Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2022 Feb 10;65(3):2571-2592. doi: 10.1021/acs.jmedchem.1c02002.